52 results about "Tuberculosis incidence" patented technology

The invention discloses application of Incarviatone A in preparation of anti-tubercle bacillus medicaments. According to the current situation that tuberculosis morbidity and mortality rise due to high tuberculosis morbidity and presence of multiple-resistant strains of tubercle bacilli at present, the Incarviatone A has obvious tubercle bacillus inhibiting activity and good application prospect as discovered. The application of the Incarviatone A in preparation of the anti-tubercle bacillus medicaments is made public for the first time, the skeleton type is completely novel and the Incarviatone A has an unexpectedly strong tubercle bacillus inhibiting activity, so the probability that other compounds give any revelation does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently made in prevention and treatment of tubercle bacillus infection.

The invention discloses an application of Houttuynoid D in preparation of a tubercle bacillus resistant medicament. According to the current situation that the incidence and the mortality of tuberculosis rise due to high incidence of the conventional tuberculosis and appearance of multi-resistant strains of tubercle bacilli, the Houttuynoid D has the activity of remarkably inhibiting the tubercle bacilli and has a good application prospect. The invention discloses the application of the Houttuynoid D in preparation of the tubercle bacillus resistant medicament for the first time, the skeleton type belongs to a brand-new skeleton type, the Houttuynoid D has unexpected strong inhibiting activity on the tubercle bacilli, the probability of giving any revelation by other compounds does not exist, and the Houttuynoid D has predominant substantial characteristics and obviously makes a remarkable progress on prevention and treatment of tubercle bacillus infection.

The invention discloses an application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus. The application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus aims at the current situation that high tuberculosis incidence and the appearance of multiple-resistant strains of tubercle bacillus result in the rising tendency in the incidence and mortality rate of tuberculosis, and Houttuynoid A is found to have remarkable tubercle bacillus inhibitory activity and good application prospect. The application of Houttuynoid A in preparing medicines for inhibiting tubercle bacillus is disclosed for the first time, has prominent substantive features and no any possibility for other compounds to give any inspiration, and simultaneously has remarkable progress when used for preventing and treating tubercle bacillus infection.

The invention discloses an application of a quinine compound in preparing anti-tubercle bacillus drugs. A structure general formula of the quinine compound of the invention is shown in a formula (1), wherein R is H or OH. In the invention, aiming to current situations that the current tuberculosis has high morbidity, and multidrug-resistant tuberculosis (TB) strains of tubercle bacillus occur so that the morbidity and mortality of the tuberculosis are in a rising trend, and according to characteristics of anti-tubercle bacillus and tolerance tubercle bacillus activities of the quinine compound, the quinine compound is used for preparing the anti-tubercle bacillus drugs. The quinine compound of the invention is derived from marine microorganisms, is easy to be extracted, has low cost and wide application prospect, and can be used for preparing the anti-tubercle bacillus drugs.

The invention discloses application of gypensapogenin B to preparation of anti-tubercle bacillus drugs. According to the high tubercle bacillus morbidity and the emergence of mycobacterium tuberculosis multiple-resistant strain, the tubercle bacillus morbidity and mortality are one the rise; and gypensapogenin B has remarkable tubercle bacillus suppression activity and good application prospect. The application of gypensapogenin B to the preparation of the anti-tubercle bacillus drugs is firstly publicized, the skeleton type is brand-new, the tubercle bacillus suppression activity is unexpectedly strong and the possibility of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in the prevention and treatment of the tubercle bacillus infection is made at the same time.

The invention relates to a recombinant tuberculosis vaccine, its preparation method and application. The vaccine of the present invention can effectively enhance the specific type I cellular immunity of the vaccinated population, and strengthen the immune protection of the vaccinated population against tuberculosis; Mycobacterium population is ineffective, to reduce the incidence of tuberculosis.